Who are Fabrazyme (agalsidase beta)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Fabagal® (Agalsidase beta), Alglucosidase alfa (GZ419829), PRX-102 (pegunigalsidase alfa).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/fabrazyme-agalsidase-beta.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Fabrazyme (agalsidase beta) — Competitive Intelligence Brief

Fabrazyme (agalsidase beta) (Fabrazyme (agalsidase beta)) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Enzyme replacement therapy (ERT); recombinant enzyme. Area: Metabolic.

marketed Enzyme replacement therapy (ERT); recombinant enzyme α-galactosidase A (GLA gene product); substrate: globotriaosylceramide (GL-3) Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

Fabrazyme (agalsidase beta) (Fabrazyme (agalsidase beta)) — Genzyme, a Sanofi Company.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Fabrazyme (agalsidase beta) TARGET	Fabrazyme (agalsidase beta)	Genzyme, a Sanofi Company	marketed	Enzyme replacement therapy (ERT); recombinant enzyme	α-galactosidase A (GLA gene product); substrate: globotriaosylceramide (GL-3)
Fabagal® (Agalsidase beta)	Fabagal® (Agalsidase beta)	ISU Abxis Co., Ltd.	phase 3	Enzyme replacement therapy (ERT)	α-galactosidase A (GLA enzyme)
Alglucosidase alfa (GZ419829)	Alglucosidase alfa (GZ419829)	Genzyme, a Sanofi Company	phase 3	Enzyme replacement therapy (ERT)	Acid alpha-glucosidase (GAA)
PRX-102 (pegunigalsidase alfa)	PRX-102 (pegunigalsidase alfa)	Protalix	phase 3	Enzyme replacement therapy (ERT)	α-galactosidase A (GLA)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Enzyme replacement therapy (ERT); recombinant enzyme class)

Genzyme, a Sanofi Company · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Fabrazyme (agalsidase beta) — Competitive Intelligence Brief. https://druglandscape.com/ci/fabrazyme-agalsidase-beta. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab